The medical device sector has been one that has seen some severe multiple compression in recent years where, instead of paying close to 20x earnings for a steady 10% annual growth rate, now the market seems content to only pay 12-14x earnings. The result is that these stocks have been cruelly punished to the point where they are looking nearly criminally cheap. Even in a time of normal interest rates it makes sense to buy stock in a company trading at 20x earnings with a 10% annual growth rate provided that it also has some dividend yield. At 3-4% interest rates when these companies are still reliably delivering strong profit growth these companies look quite cheap. Specifically, I am speaking of:
Johnson and Johnson (JNJ)
Zimmer Holdings (ZMH)
One thing I like about all of these compared to pharmaceutical companies is that they are not as subject to patent risk. Medical devices are far harder to produce "generics" for as not just any mom and pop manufacturing firm can whip together pacemakers or spinal implants. Even if they did, the liabilities would be tremendous. That's not as true with generic drugs. Once you know how to do the chemical formula, it's fairly simple. Of course, I am speaking as someone who didn't do too well in chemistry, but empirically speaking this seems to be true. These companies do periodically get hit with government probes and lawsuits, but rarely have they gone anywhere.
I personally own Medtronic and it has been a source of frustration as it has delivered on its earnings growth targets, but it has seen its PE multiple shrink down to the point it now trades at 9.8x next year's forecast earnings. That's absurd for a company growing 10% a year. It once traded at close to 23x earnings when I first bought it. Similarly, Johnson and Johnson trading at 11.4x next year's earnings is also very cheap, especially as it pays a 3.6% dividend even if it doesn't go anywhere. I'll take 3.6% given that ten year treasuries give so less. Zimmer trades at 11.8x next year's earnings with a growth rate even higher than JNJ or Medtronic. Its downfall is that it doesn't pay a dividend.
If I had to recommend only one of these, I would say JNJ is the best bet for a core position. That dividend yield on top of 8-10% annual earnings growth is hard to say no to. Also, it has more diverse product lines, though medical devices provided the real oomph to the growth rate. Still, the diversity does insulate it from being hamstrung by a liability issue in any one product line.
In all of this you will note that I did not mention Boston Scientific (BSX). This is for good reason. That stock is garbage and it only brings sadness and woe to all who own it. Leave it alone to fester and decay in the pits of stock hell.